Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG: 9989)

Shenzhen Hepalink Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,243	1,852	2,139	2,944	2,712	1,278
Short-Term Investments	-	-	-	-	74.21	-
Trading Asset Securities	836.8	414.18	1,312	981.16	828.21	112.64
Cash & Short-Term Investments	3,080	2,266	3,450	3,925	3,615	1,390
Cash Growth	35.94%	-34.33%	-12.10%	8.59%	159.98%	-30.28%
Accounts Receivable	1,210	1,275	1,626	1,543	1,694	1,316
Other Receivables	91.36	120.43	134.82	243.81	184.16	389.02
Receivables	1,302	1,395	1,761	1,787	1,878	1,705
Inventory	5,613	6,654	6,844	4,708	3,168	2,374
Other Current Assets	377.7	289.01	334.53	349.43	467.34	525.4
Total Current Assets	10,372	10,604	12,390	10,770	9,129	5,996
Property, Plant & Equipment	2,633	2,634	2,477	2,537	2,571	2,576
Long-Term Investments	1,881	2,514	2,464	2,618	3,999	3,280
Goodwill	2,298	2,322	2,351	2,152	2,203	2,355
Other Intangible Assets	429.91	474.57	522.87	546.87	615.95	671.9
Long-Term Deferred Tax Assets	271.15	320.5	141.48	121.72	83.94	117.75
Long-Term Deferred Charges	209.66	211.07	244.71	241.88	230.33	132.06
Other Long-Term Assets	26.95	122.79	224.95	120.85	194.36	114.89
Total Assets	18,121	19,203	20,816	19,108	19,026	15,242
Accounts Payable	344	302.22	427.43	385.79	239.22	228.66
Accrued Expenses	108.57	371.92	377.51	398.43	395.33	355.24
Short-Term Debt	1,944	1,881	2,385	1,886	1,860	2,927
Current Portion of Long-Term Debt	1,110	1,744	1,635	1,382	622.21	1,014
Current Portion of Leases	-	37.8	35.69	31.75	25.6	-
Current Income Taxes Payable	217.58	157.18	112.3	113.2	43.74	63.42
Current Unearned Revenue	256.39	366.17	433.88	383.79	265.04	203.36
Other Current Liabilities	360.7	126.32	168.2	210.34	161.93	174.56
Total Current Liabilities	4,341	4,986	5,576	4,791	3,613	4,967
Long-Term Debt	1,193	1,810	2,297	2,250	3,086	2,355
Long-Term Leases	63.72	90.42	110.75	104	51.64	-
Long-Term Unearned Revenue	27.21	30.43	32.55	16.67	18.74	20.82
Long-Term Deferred Tax Liabilities	239.57	252.57	328.92	275.36	427.67	302
Other Long-Term Liabilities	10.09	14.31	29.39	26.44	24.76	17.48
Total Liabilities	5,907	7,215	8,407	7,585	7,337	7,771
Common Stock	1,467	1,467	1,467	1,467	1,467	1,247
Additional Paid-In Capital	5,869	6,356	5,859	5,944	6,035	2,634
Retained Earnings	4,711	3,931	4,861	4,184	4,212	3,411
Comprehensive Income & Other	92.86	158.46	125.52	-183.36	-145.09	55.12
Total Common Equity	12,140	11,913	12,313	11,411	11,569	7,347
Minority Interest	74.14	75.23	96.72	111.96	119.6	124.1
Shareholders' Equity	12,215	11,988	12,409	11,523	11,689	7,471
Total Liabilities & Equity	18,121	19,203	20,816	19,108	19,026	15,242
Total Debt	4,310	5,563	6,464	5,654	5,645	6,297
Net Cash (Debt)	-1,231	-3,297	-3,013	-1,729	-2,030	-4,906
Net Cash Per Share	-0.84	-2.25	-2.05	-1.18	-1.50	-3.93
Filing Date Shares Outstanding	1,467	1,467	1,467	1,467	1,467	1,247
Total Common Shares Outstanding	1,467	1,467	1,467	1,467	1,467	1,247
Working Capital	6,031	5,618	6,814	5,978	5,516	1,028
Book Value Per Share	8.27	8.12	8.39	7.78	7.88	5.89
Tangible Book Value	9,413	9,116	9,439	8,712	8,751	4,320
Tangible Book Value Per Share	6.42	6.21	6.43	5.94	5.96	3.46
Land	-	34	33.43	30.61	31.32	-
Buildings	-	1,791	1,480	1,450	1,445	-
Machinery	-	1,952	1,892	1,719	1,693	-
Construction In Progress	-	468.72	394.53	425.35	364.39	-

Source: S&P Capital IQ. Standard template. Financial Sources.